article thumbnail

Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and meta‐analysis

European Journal of Heart Failure

Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidney disease (ESKD) undergoing dialysis is limited.

article thumbnail

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR?Preserved analysis

European Journal of Heart Failure

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide. Patients who developed LRTI had a 2.7-fold

article thumbnail

Mineralocorticoid Receptor Antagonists in Heart Failure: An Update

Circulation: Heart Failure

Spironolactone reduced HF events in some patients with HF with preserved ejection fraction, but the results were not generalizable to all patients with HF with preserved ejection fraction. The use of MRAs has been limited due to excessive concern about hyperkalemia.

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 103
article thumbnail

Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry

Open Heart

HF with preserved ejection fraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3% Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). and 29.2%, p<0.001).

article thumbnail

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), but also in those with coronary heart disease. [5, Carbone, Salvatore, et al. 2017): 451-463.

Obesity 52